Compare PEBK & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBK | AVXL |
|---|---|---|
| Founded | 1912 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.4M | 237.2M |
| IPO Year | 2012 | 2013 |
| Metric | PEBK | AVXL |
|---|---|---|
| Price | $43.14 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 34.6K | ★ 1.4M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.81 | $2.41 |
| 52 Week High | $45.78 | $13.99 |
| Indicator | PEBK | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 47.34 |
| Support Level | $41.32 | $2.62 |
| Resistance Level | $45.78 | $2.80 |
| Average True Range (ATR) | 1.49 | 0.15 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 37.47 | 57.69 |
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.